Teriflunomide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1016 publications

Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders.

Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders.

Journal: Continuum (Minneapolis, Minn.)

Published: April 02, 2026

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Journal: JAMA neurology

Published: February 16, 2026

Cladribine for people with multiple sclerosis.

Cladribine for people with multiple sclerosis.

Journal: The Cochrane database of systematic reviews

Published: January 09, 2026

Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment.

Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment.

Journal: International journal of molecular sciences

Published: December 28, 2025

NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple Sclerosis.

NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: December 23, 2025

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

Journal: Multiple sclerosis and related disorders

Published: December 20, 2025

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: December 16, 2025

From Multiple Sclerosis to Spondyloarthritis: A Case of Teriflunomide-Associated Immune-Mediated Disease.

From Multiple Sclerosis to Spondyloarthritis: A Case of Teriflunomide-Associated Immune-Mediated Disease.

Journal: Joint bone spine

Published: December 07, 2025

Design of a Thermoresponsive Nose-to-Brain Neuromaterial for the Release of Naturally Derived Extracellular Vesicles Delivering Teriflunomide for Multiple Sclerosis.

Design of a Thermoresponsive Nose-to-Brain Neuromaterial for the Release of Naturally Derived Extracellular Vesicles Delivering Teriflunomide for Multiple Sclerosis.

Journal: AAPS PharmSciTech

Published: November 17, 2025

Effects of dihydroorotate dehydrogenase inhibition and vitamin E supplementation on ferroptosis-related processes and post-mortem meat quality in broiler chickens.

Effects of dihydroorotate dehydrogenase inhibition and vitamin E supplementation on ferroptosis-related processes and post-mortem meat quality in broiler chickens.

Journal: Animal bioscience

Published: November 04, 2025

Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review.

Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review.

Journal: Journal of autoimmunity

Published: November 04, 2025

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal: Journal of neurology

Published: November 03, 2025

Showing 1-12 of 1,016

Last Updated: 04/28/2026